Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Another weight-loss jab will hit pharmacy shelves in Ireland at the end of next month – but it will only be available on ...

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The ...

For the first time a semaglutide weight loss drug has been approved for use in Australia to also treat cardiovascular disease in obese and overweight patients.

This was significantly higher than the reduction achieved with standard dose Wegovy, 2.4mg, and the placebo, which resulted in losses of 17.5% and 2.4%, respectively. In addition, 33.2% of ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 ... starter dose and 42,960 yen for a 2.4 mg dose, Novo said. Patients in Japan will be ...

Wegovy's sales fell slightly short of ... 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.

Opens in a new tab or window Patients treated with semaglutide 7.2 mg achieved a 20.7% weight loss after 72 weeks compared with a reduction of 17.5% with semaglutide 2.4 mg (Wegovy) and 2.4% with ...

The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...